سعر باراميب مركب 20 قرص 250 مجم / 250 مجم 2023

Paramibe Compound tablets containing diiodohydroxyquinoline 250 mg + metronidazole 250 mg, pack of 20 tablets, manufactured by CID (Chemical Industries Development, Egypt).

• Hypersensitivity to metronidazole or other nitroimidazole derivatives.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Do not use in patients who have taken disulfiram within the last two weeks (psychotic reactions reported).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Avoid alcohol and propylene glycol-containing products during and for at least three days after therapy (disulfiram-like reaction).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed warning: metronidazole has been carcinogenic in mice and rats; avoid unnecessary use.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Encephalopathy and peripheral neuropathy (including optic neuropathy) have been reported; CNS symptoms are generally reversible after discontinuation.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• DisulfiramPsychotic reactions reported with concurrent use; do not give metronidazole within two weeks of disulfiram.DailyMed (U.S. National Library of Medicine)
• AlcoholDisulfiram-like reaction (abdominal cramps, nausea, vomiting, headache, flushing).DailyMed (U.S. National Library of Medicine)

• Metronidazole: no adequate controlled studies in pregnancy; published data in more than 5,000 pregnant women did not consistently show an increased risk of malformations. In trichomoniasis it is contraindicated in the first trimester.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Diiodohydroxyquinoline (iodoquinol):
• Metronidazole: Reduced intracellularly in susceptible anaerobes to reactive intermediates that interact with DNA, inhibiting nucleic acid synthesis (US label).